Ingrum Bankston
Urology · Tuscaloosa, ALNPI 1851357891
Payments from drug & device makers
Across 270 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$780
- AbbVie$745
- Coloplast$310
- Dendreon Pharmaceuticals LLC$303
- Bayer$262
- Endo Pharmaceuticals Inc.$217
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,35690%
- Education$49110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 41 | $780 |
| AbbVie(2 entities) | 53 | $745 |
| Coloplast | 12 | $310 |
| Dendreon Pharmaceuticals LLC | 9 | $303 |
| Bayer | 15 | $262 |
| Endo Pharmaceuticals Inc. | 14 | $217 |
| Myriad Genetic Laboratories, Inc. | 11 | $204 |
| Johnson & Johnson | 12 | $179 |
| Pfizer | 11 | $174 |
| Antares Pharma, Inc. | 8 | $153 |
| Sumitomo Pharma America, Inc. | 9 | $153 |
| Urovant Sciences Inc | 9 | $148 |
| Blue Earth Diagnostics | 6 | $140 |
| Boston Scientific | 5 | $110 |
| Clarus Therapeutics Inc. | 7 | $106 |
| Rochester Medical Corporation | 5 | $100 |
| Myovant Sciences Inc. | 6 | $98 |
| Medtronic(2 entities) | 4 | $86 |
| Amgen | 5 | $85 |
| Progenics Pharmaceuticals, Inc. | 3 | $51 |
| Halozyme Inc | 2 | $51 |
| Axonics, Inc. | 3 | $44 |
| Merck | 2 | $42 |
| Urogen Pharma, Inc. | 2 | $33 |
| Photocure Inc | 2 | $28 |
| Tolmar, Inc. | 1 | $28 |
| Laborie Medical Technologies Corp. | 2 | $27 |
| Sanofi | 1 | $25 |
| Neotract Inc. | 1 | $21 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| 180 Medical, Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Mission Pharmacal Company | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Innovation Technologies Inc | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
How this compares
$4,847 in reported general payments places this provider in the 55th percentile of 179 urology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 38 | $26,764 |
| GemtesaVibegron | 38 | $23,059 |
| Potassium Citrate ErPotassium Citrate | 19 | $2,821 |
| Tamsulosin Hcl | 96 | $1,633 |
| Dutasteride | 35 | $1,210 |
| Solifenacin Succinate | 17 | $371 |
| Finasteride | 34 | $341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $780 | $26,76438 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $153 | $23,05938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 179 urology providers in Alabama.
Other urology in Tuscaloosa
- Raymond PooreTuscaloosa$12K
- John DuffyTuscaloosa$8K
- James McMurrayHuntsville$4.7M
- Vincent BivinsHomewood$1.3M
- Charles WhiteMobile$735K
- Thomas ChiBirmingham$628K
- Charles BuggHomewood$544K
- Charles PeytonBirmingham$543K
- Brian ChristineHomewood$372K
- Austin LutzHomewood$367K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.